Pathstone Family Office’s Ginkgo Bioworks DNA Stock Holding History

Pathstone Family Office’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$293K	Buy	4,044 +1,782	+79%	+$142K	﹤0.01%	1321
2023 Q2	$168K	Hold	2,262	–	–	﹤0.01%	1167
2023 Q1	$120K	Sell	2,262 -507	-18%	-$32.1K	﹤0.01%	1122
2022 Q4	$187K	Sell	2,769 -6	-0.2%	-$552	﹤0.01%	1393
2022 Q3	$346K	Buy	2,775 +2,267	+446%	+$270K	﹤0.01%	1191
2022 Q2	$48.6K	Buy	508 +4	+0.8%	+$488	﹤0.01%	1021
2022 Q1	$82K	Buy	504 +4	+0.8%	+$779	﹤0.01%	931
2021 Q4	$166K	Buy	+500	New	+$238K	﹤0.01%	844

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Pathstone Family Office's DNA Position: Q3 2023 in Review

Pathstone Family Office increased its Ginkgo Bioworks (DNA) stake by 79% in Q3 2023, buying an estimated $142K and bringing the position to 4,044 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

Pathstone Family Office first reported a position in DNA in Q4 2021 and has held it in 8 quarters since. The position peaked at $346K in Q3 2022. 349 funds tracked by Wall St. Rank hold DNA as of Q3 2023.

Pathstone Family Office held 4,044 shares of Ginkgo Bioworks worth $293K as of Q3 2023.
Pathstone Family Office bought 1,782 Ginkgo Bioworks shares in Q3 2023, an estimated $142K.
Ginkgo Bioworks made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1321 holding.
Pathstone Family Office first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 8 quarters since.
Pathstone Family Office's Ginkgo Bioworks position peaked at $346K in Q3 2022.
349 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.